Outcomes in patients with aggressive B‐cell non‐Hodgkin lymphoma after intensive frontline treatment failure
Sign Up to like & getrecommendations! Published in 2019 at "Cancer"
DOI: 10.1002/cncr.32526
Abstract: Salvage immunochemotherapy followed by high‐dose chemotherapy and autologous stem cell transplantation is the standard‐of‐care second‐line treatment for patients with relapsed/refractory diffuse large B‐cell lymphoma after first‐line R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Outcomes after… read more here.
Keywords: patients aggressive; lymphoma; aggressive cell; line ... See more keywords
Treatment of aggressive B‐cell lymphomas
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2407
Abstract: The treatment of aggressive B‐cell lymphomas is in evolution, largely based on the recognition of major genetic and biologic subtypes harboring distinct pathogenetic lesions. In this review, we will consider current treatment options with the… read more here.
Keywords: aggressive cell; chop; treatment; cell lymphomas ... See more keywords
TP53 mutation and survival in aggressive B cell lymphoma
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Cancer"
DOI: 10.1002/ijc.30838
Abstract: TP53 is mutated in 20–25% of aggressive B‐cell lymphoma (B‐NHL). To date, no studies have addressed the impact of TP53 mutations in prospective clinical trial cohorts. To evaluate the impact of TP53 mutation to current… read more here.
Keywords: tp53 mutation; aggressive cell; tp53; tp53 mutations ... See more keywords
Lenalidomide in combination with rituximab, dexamethasone, high-dose ARA-C and cisplatinum as salvage therapy in refractory or relapsed aggressive B-cell non-hodgkin-lymphoma - an open-label, multicentre phase I/II study (DSHNHL-R6)
Sign Up to like & getrecommendations! Published in 2025 at "Annals of Hematology"
DOI: 10.1007/s00277-025-06355-5
Abstract: Treatment of relapsed or refractory aggressive B-cell lymphoma (aNHL) is still an unmet medical need. Platinum-containing salvage immunotherapies achieve remission rates of 40–60%. The phase I/II DSHNHL-R6 trial sought to investigate feasibility, safety and efficacy… read more here.
Keywords: aggressive cell; lenalidomide combination; salvage; lymphoma ... See more keywords
Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT
Sign Up to like & getrecommendations! Published in 2022 at "Signal Transduction and Targeted Therapy"
DOI: 10.1038/s41392-022-00924-0
Abstract: TP53 gene alteration confers inferior prognosis in refractory/relapse aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL). From September 2016 to September 2020, 257 r/r B-NHL patients were assessed for eligibility for two trials in our center, assessing… read more here.
Keywords: combination; tp53 alterations; aggressive cell; car19 cell ... See more keywords
Computational modelling of aggressive B-cell lymphoma
Sign Up to like & getrecommendations! Published in 2025 at "Biochemical Society Transactions"
DOI: 10.1042/bst20253039
Abstract: Decades of research into the molecular signalling determinants of B cell fates, and recent progress in characterising the genetic drivers of lymphoma, has led to a detailed understanding of B cell malignancies but also revealed… read more here.
Keywords: cell lymphoma; aggressive cell; modelling aggressive; computational models ... See more keywords
Another disappointment in treating relapsed, refractory high‐risk aggressive B‐cell lymphomas
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Haematology"
DOI: 10.1111/bjh.16259
Abstract: Optimising outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) remains one of the greatest challenges still facing haemato-oncologists today. The SCHOLAR-1 analysis pooled trial and retrospective data (n = 636) and… read more here.
Keywords: relapsed refractory; trial; aggressive cell; pixantrone ... See more keywords
Aggressive B‐cell lymphomas with a primary bone marrow presentation
Sign Up to like & getrecommendations! Published in 2020 at "Histopathology"
DOI: 10.1111/his.14124
Abstract: Aggressive B‐cell lymphomas present as a heterogeneous spectrum of disease. A primary diagnosis in the bone marrow (BM) may be challenging in terms of diagnostic classification and clinical handling, owing to limited architectural information. Aggressive… read more here.
Keywords: presentation; aggressive cell; lymphomas primary; cell lymphomas ... See more keywords
Value of cerebrospinal fluid white cell count and protein level in predicting leptomeningeal involvement by systemic aggressive B‐cell lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Laboratory Hematology"
DOI: 10.1111/ijlh.13815
Abstract: Diagnostic cerebrospinal fluid (CSF) analysis for patients with newly diagnosed aggressive B‐cell lymphoma at risk of secondary central nervous system involvement typically includes multiparametric flow cytometry (MFC), cytology (CC), white cell count (WCC) and total… read more here.
Keywords: cell; aggressive cell; cell count; white cell ... See more keywords
Abstract 4225: CG-806, a first-in-class FLT3/BTK inhibitor, and venetoclax synergize to inhibit cell proliferation and to induce apoptosis in aggressive B-cell lymphomas
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-4225
Abstract: Double/triple-hit lymphomas (DHL/THL, harboring concurrent MYC, BCL2 and/or BCL6 rearrangements) and double-expressor lymphomas (DEL, with MYC/BCL2 co-overexpression without underlying rearrangements) account for 7-12% and 20-30% of diffuse large B-cell lymphomas (DLBCLs), respectively, and have poor… read more here.
Keywords: venetoclax; aggressive cell; cell lymphomas; proliferation ... See more keywords
Pharmacoproteomics Identifies PLK1 As Vulnerability for Aggressive B-Cell Lymphomas
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-118004
Abstract: Background: c-MYC is a transcription factor that promotes oncogenesis by activating and repressing its target genes that control cell growth, metabolism, and proliferation. MYC is deregulated in a large proportion of aggressive B-cell lymphomas. A… read more here.
Keywords: aggressive cell; myc; research funding;